AU2008289653B2 - MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy - Google Patents

MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy Download PDF

Info

Publication number
AU2008289653B2
AU2008289653B2 AU2008289653A AU2008289653A AU2008289653B2 AU 2008289653 B2 AU2008289653 B2 AU 2008289653B2 AU 2008289653 A AU2008289653 A AU 2008289653A AU 2008289653 A AU2008289653 A AU 2008289653A AU 2008289653 B2 AU2008289653 B2 AU 2008289653B2
Authority
AU
Australia
Prior art keywords
thioxo
tetrahydro
methyl
purin
mpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008289653A
Other languages
English (en)
Other versions
AU2008289653A1 (en
Inventor
Hakan Eriksson
Werner Poewe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008289653A1 publication Critical patent/AU2008289653A1/en
Application granted granted Critical
Publication of AU2008289653B2 publication Critical patent/AU2008289653B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2008289653A 2007-08-23 2008-08-22 MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy Ceased AU2008289653B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
US60/957,525 2007-08-23
US60/957,523 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (2)

Publication Number Publication Date
AU2008289653A1 AU2008289653A1 (en) 2009-02-26
AU2008289653B2 true AU2008289653B2 (en) 2012-06-28

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008289653A Ceased AU2008289653B2 (en) 2007-08-23 2008-08-22 MIPO inhibitors for the treatment of Huntington's disease and multiple system atrophy

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN105687199A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
ES2587954T3 (es) * 2012-03-29 2016-10-27 Basf Se Compuestos de hetero-bicíclicos N-sustituidos y derivados para combatir plagas animales II
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
CR20170498A (es) 2015-05-05 2018-01-26 Pfizer 2-tiopirimidinonas
CA3067591A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
IL272043B (en) * 2017-07-17 2022-09-01 Astrazeneca Ab mpo inhibitors for use in medicine
AU2020363903A1 (en) * 2019-10-10 2022-03-24 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
WO2021226161A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
JP2025528217A (ja) 2022-08-18 2025-08-26 アストラゼネカ・アクチエボラーグ ミエロペルオキシダーゼの阻害剤
CA3266275A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab PHARMACEUTICAL FORMULATION
EP4624473A1 (en) * 2022-12-09 2025-10-01 Shenzhen Salubris Pharmaceuticals Co., Ltd. Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089430A1 (en) * 2002-04-19 2003-10-30 Astrazeneca Ab Thioxanthine derivatives as myeloperoxidase inhibitors
WO2006062465A1 (en) * 2004-12-06 2006-06-15 Astrazeneca Ab Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264210T3 (es) * 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089430A1 (en) * 2002-04-19 2003-10-30 Astrazeneca Ab Thioxanthine derivatives as myeloperoxidase inhibitors
WO2006062465A1 (en) * 2004-12-06 2006-06-15 Astrazeneca Ab Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Also Published As

Publication number Publication date
CN105687199A (zh) 2016-06-22
KR101588464B1 (ko) 2016-01-25
US20090054468A1 (en) 2009-02-26
HRP20130139T1 (hr) 2013-03-31
US20110207755A1 (en) 2011-08-25
BRPI0815681A2 (pt) 2015-02-18
CY1113714T1 (el) 2016-06-22
HK1145141A1 (en) 2011-04-08
US20200405724A1 (en) 2020-12-31
EP2200616B1 (en) 2012-12-26
MY155633A (en) 2015-11-13
CA2698205A1 (en) 2009-02-26
CA2698205C (en) 2016-06-21
AU2008289653A1 (en) 2009-02-26
ZA201000848B (en) 2012-07-25
IL203738A (en) 2015-08-31
ME01510B (me) 2014-04-20
MX2010001983A (es) 2010-03-10
JP2010536849A (ja) 2010-12-02
CN113633641A (zh) 2021-11-12
US10772890B2 (en) 2020-09-15
JP2013151547A (ja) 2013-08-08
CN101873857A (zh) 2010-10-27
CN103638029A (zh) 2014-03-19
EP2200616A4 (en) 2010-08-25
DK2200616T3 (da) 2013-03-04
US20130059870A1 (en) 2013-03-07
EP2200616A1 (en) 2010-06-30
IL240130A0 (en) 2015-09-24
WO2009025618A1 (en) 2009-02-26
RS52665B (sr) 2013-06-28
EA201000202A1 (ru) 2010-10-29
NZ584135A (en) 2012-04-27
US20190099423A1 (en) 2019-04-04
SI2200616T1 (sl) 2013-03-29
US20140221400A1 (en) 2014-08-07
EA017510B1 (ru) 2013-01-30
PT2200616E (pt) 2013-02-27
KR20100055434A (ko) 2010-05-26
JP5247804B2 (ja) 2013-07-24
ES2399846T3 (es) 2013-04-03
PL2200616T3 (pl) 2013-04-30
PH12014501180A1 (en) 2015-08-24

Similar Documents

Publication Publication Date Title
US10772890B2 (en) Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938
JP6811203B2 (ja) 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
EP2916868B1 (en) Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
Liou et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor
US8592420B2 (en) Method of treating an anxiety disorder
WO1999026627A1 (en) (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
EP2355657A1 (en) Compositions and methods of treating endothelial disorders
US20090053176A1 (en) New Combination 937
EP3615022A1 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
US20120094985A1 (en) Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
HK1145141B (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
Lapin et al. Antiethanol effects of indol-3-ylpyruvic acid in mice
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途
US20110046141A1 (en) Use of pde5 inhibitors for treating circadian rhythm disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired